JADE101 not checked

Jade Biosciences, Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
3 active
4 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“JADE101 is supplied as sterile solution to be administered by SC injection.”In the company’s words, NCT07902817 on ClinicalTrials.gov
Tested for
IgA Nephropathy (IgAN), IgA Nephropathy
Main trialPhase 3
“This Phase 3 study will evaluate the safety and efficacy of JADE101 compared with placebo in adults with immunoglobulin A nephropathy (IgAN). The results will contribute to the overall clinical characterization of JADE101 in this patient population.”In the company’s words, NCT07902817 on ClinicalTrials.gov

Other drugs for IgA Nephropathy (IgAN)

All 39 drugs for IgA Nephropathy (IgAN)

Coming up3

Changes2

Last 90 days

Trials4

TrialPhaseCompletesWhat it tests
Phase 3Recruiting Jun 2029 A Phase 3 Blinded Study of JADE101 in Participants With Immunoglobulin A Nephropathy
Phase 2Recruiting Jan 2029 A Study of JADE101 in Participants With Immunoglobulin A Nephropathy
Phase 1Recruiting May 2027 A Single Dose, Phase 1 Study of JADE101 in Healthy Japanese and Chinese Participants
Phase 1Completed 21 Oct 2026 A Phase 1 Study of JADE101 in Healthy Participants
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow JADE101

Following is part of Solo: you see every change to JADE101 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in